Clinical research
Eribulin improves survival in women with advanced breast cancer
Source: Wikimedia Commons
Eribulin improves survival in women with advanced breast cancer
The chemotherapy drug eribulin mesylate (Halaven) was originally derived from a sea sponge and acts by blocking microtubule formation. According to new research, eribulin improves overall survival in women with advanced breast cancer, with the greatest benefit seen in women with triple-negative disease.
Researchers led by Chris Twelves, from the University of Leeds, pooled data from two phase III open-label trials of eribulin in 1,864 women with locally recurrent or metastatic breast cancer who had previously received an anthracycline and a taxane[1].
Eribulin was associated with a significant 2.4-month improvement in overall survival versus standard therapy; among women with triple-negative breast cancer, this rose to 4.7 months. “Although eribulin isn’t a cure, it’s an extra treatment option,” said Twelves.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067096
Recommended from Pharmaceutical Press
- Previous
- Next
Community Pharmacy Handbook
Community Pharmacy Handbook is a survival guide for community pharmacists and students, answering your practical questions. Includes case studies.
£33.00Buy now
FASTtrack: Pharmacology
FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.
£28.00Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.